This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Rocket Stocks to Buy Ahead of Earnings Season

Sanofi

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

First up is French drug maker Sanofi (SNY). While shares of Sanofi have gotten knocked around by the recent drama in the EU, this stock is still faring well against the S&P 500 this year -- the stock is up close to 18% since the first trading day in January. Now, with analyst sentiment on the upswing, we're betting on shares.

>>5 Biotech Stocks Poised for Breakouts

Sanofi is one of the big pharma names with the lease exposure to the U.S. Only around 30% of the firm's sales are generated stateside, with another 30% earned in the EU. That diversified income statement is a good thing for SNY shareholders because it reduces the potential for regulatory headwinds that could impact sales of SNY's drug portfolio. Hefty exposure to emerging markets also bodes very well for Sanofi shareholders, given the pace that developing countries are consuming new drug treatments.

While competition is tough in the pharma business, Sanofi has done an enviable job of focusing more on unique drugs that have more defensible moats. The firm's acquisition of Genzyme was pricey, but it adds some attractive biopharmaceutical names to SNY's pipeline. That also helps to offset the patent expiration cliff that many of Sanofi's peers are facing right now.

A 3.92% dividend yield sweetens the pot for investors looking for a mix of value and income right now.

Sanofi also shows up on a recent list of 9 Stocks to Buy for a European Recovery.

2 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,105.22 +18.59 0.11%
S&P 500 1,990.70 +3.69 0.19%
NASDAQ 4,481.3540 +7.6570 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs